Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Yingjuan Fan"'
Autor:
Lingyu Zhang, Yingting Zhuang, Guihui Tu, Ding Li, Yingjuan Fan, Shengnan Ye, Jianhua Xu, Ming Zheng, Ying Wu, Lixian Wu
Publikováno v:
ACS Omega, Vol 7, Iss 3, Pp 2571-2582 (2022)
Externí odkaz:
https://doaj.org/article/bf06c3ddc1db40d391c5bc62df249542
Autor:
Bi Liu, Yunzhu Shen, Huafang Huang, Kimiko Della Croce, Min Wu, Yingjuan Fan, Yang Liu, Jianhua Xu, Guang Yao
Publikováno v:
Cell Communication and Signaling, Vol 18, Iss 1, Pp 1-15 (2020)
Abstract Background Relapsed leukemia following initial therapeutic response and remission is difficult to treat and causes high patient mortality. Leukemia relapse is due to residual quiescent leukemia cells that escape conventional therapies and la
Externí odkaz:
https://doaj.org/article/6513690e95924ea0bad2773c924e17b8
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 7, Iss 1, Pp 91-96 (2017)
The aims of the present study were to estimate the affinity between 3,5-(E)-bis(3-methoxy-4-hydroxybenzal)-4-piperidinone hydrochloride (C0818) and heat shock protein 90 (Hsp90) and to investigate the inhibitory effects of this compound on Hsp90 ATPa
Externí odkaz:
https://doaj.org/article/cfa83402e5b145ab8e3994c3a4e1c5e1
Autor:
Jianhua Xu, Yuanzhong Chen, Yong Wu, Meijuan Huang, Pinzhang Gao, Yingjuan Fan, Lisen Huang, Ying Wu, Liguang Lou, Yang Liu, Ruijia Chen, Jing Yu, Lixian Wu
Supplementary Figure S6. The scheme of origins of LSCs and the effects of C086 on LSCs via eradicate leukemia cells at different mature state.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e6a1abe0a3202a782de112f4c040c68
https://doi.org/10.1158/1078-0432.22459397
https://doi.org/10.1158/1078-0432.22459397
Autor:
Jianhua Xu, Yuanzhong Chen, Yong Wu, Meijuan Huang, Pinzhang Gao, Yingjuan Fan, Lisen Huang, Ying Wu, Liguang Lou, Yang Liu, Ruijia Chen, Jing Yu, Lixian Wu
Supplementary Methods and Materials, Figure Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f91df829edb8ec7a691abf9246b82b6
https://doi.org/10.1158/1078-0432.22459394
https://doi.org/10.1158/1078-0432.22459394
Autor:
Jianhua Xu, Yuanzhong Chen, Yong Wu, Meijuan Huang, Pinzhang Gao, Yingjuan Fan, Lisen Huang, Ying Wu, Liguang Lou, Yang Liu, Ruijia Chen, Jing Yu, Lixian Wu
Purpose: Although tyrosine kinase inhibitors (TKI) such as imatinib provide an effective treatment against Bcr-Abl kinase activity in the mature cells of patients with chronic myelogenous leukemia (CML), TKIs probably cannot eradicate the leukemia st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a5dbdf0b80c36e6009e6099853bf9b2
https://doi.org/10.1158/1078-0432.c.6524213
https://doi.org/10.1158/1078-0432.c.6524213
Publikováno v:
Acta Pharmacol Sin
Heat shock protein 90 (Hsp90) is the most common molecular chaperone that controls the maturation of many oncoproteins critical in tumor development. Hsp90 has been considered as a promising target for cancer treatment, but the clinical significance
Publikováno v:
Cancer Management and Research. 11:8937-8945
Purpose Inhibition of heat shock protein 90 (Hsp90) can lead to degradation of multiple client proteins, which are involved in tumor progression. Elevated Hsp90 expression has been linked to poor prognosis in patients with non-small cell lung cancer
Autor:
Ding Li, Xianling Chen, Jianhua Xu, Yingjuan Fan, LingYu Zhang, Lixian Wu, Tingting Wang, Yuanzhong Chen, Yingting Zhuang, Yufei Luo
Publikováno v:
Molecular Cancer Research. 17:761-772
NF-κB mediates acquired resistance in acute myeloid leukemia (AML) cells treated with DNA-damaging agents. Because DNA repair is the major molecular shift that alters sensitivity to DNA-damaging agents, we explored whether activation of the NF-κB p
Autor:
Yang Liu, Huafang Huang, Bi Liu, Jianhua Xu, Guang Yao, Yunzhu Shen, Kimiko Della Croce, Min Wu, Yingjuan Fan
Publikováno v:
Cell Communication and Signaling : CCS
Cell Communication and Signaling, Vol 18, Iss 1, Pp 1-15 (2020)
Cell Communication and Signaling, Vol 18, Iss 1, Pp 1-15 (2020)
Background Relapsed leukemia following initial therapeutic response and remission is difficult to treat and causes high patient mortality. Leukemia relapse is due to residual quiescent leukemia cells that escape conventional therapies and later reeme